i say, there is zero news so incy will trade down through asco
no comment on the bonds, no buy side comments
only 9 page presentation, cover age, worthless, 1st page safe harbor, and good golly who puts this together, pages 7 and 9 are the same.....asleep at the wheel
no hope at the end of the tunnel
oh i guess the presentation was the bomb yesterday....not a single word and incyte would not re post the oral comments as of yesterday on there website
seems that last 300 million or was it 500 million has provided ZERO help
a win win to help block future m and a of incyte as they plod forward, to study, study, study and of course ibb up big and naz up....so you know the favorite trading place for incyte red, red and going deeper red
2nd analysts since tuesday, today, has drastically lowered earnings from .31 to .10 ........personally, i think the cat is out of the bag, i have even lowered my estimates, though not that drastically
Inside XBI’s Large Caps: Incyte Pulls Down Large Caps on Earnings Concerns
when the incy falls 2 to 3 times the rates of ibb, or other indexes it is a real bad omen............
be prepared for a bad day, again today, tomorrow, monday?
what is going to happen, when the stock market really tanks like 200, 400, or 500 points
GUESSING epacodastat trials coming to a halt
here is the previous statement
1st q estimates for incyte
analysts have a consensus of 265.7m in rev and .26 in earnings
okay looking back we have 3rd q of 2014 of 97.8m, 4th q of 2014 106.00m, 1st q of 2015 115.3.
Being that 1st q is generally the slowest sales of the year, and given we did 182m in 4th q of 2015, sales estimates for 1st q of 2016 are 201m, this comes from using a 9% increase in sales between 4th q of 2014 and 1st q of the 2015 and that there is an extra day in the q this year. Maddi states that contract rev is 58m so, I will agree to that. I will go out on royality of 27m. All total we have revenues of a whopping $286Million
Last q i estimated R&D at 140m, and it came in at 117m. SG&A at 50m and it came in at 52m.
So I see R&D at 128M and SG&A at 57M. and 20M miscellaneous. R&D and SG&A have stock grants included. Costs of 205M.
Now what I do not know , is there costs associated with the stopping of all the ruxolitinib studies, this could be a big number. Will be interesting to see if Jacosa weighs in on this. Also if there was any payments to joint partnerships, Lilly will be charged on 2nd q.
Revenue 286M less costs 205M is earnings of $81M/ share count of 195m is earnings of .415 per share Less
I would like to add, mark to market on agenus shares, based on value on march31. is 4.20 ish , purchased shares roughly 4.70, thus a loss of .50 per share...on almost 12 million shares is 6 million loss.....
I am decreasing sales by 5 million and raising overhead by 10 million
61 million in income 195 m shares gets so .313 income per share
explain to the longs why it is under 70, we are all waiting, you are just like obummer, never answer, always talk about something else.........why, because you are too stupid to say any reasons